RecruitingNot Applicable

Analysis of the Role of IgE Proteoforms in Health and Disease

Belgium200 participantsStarted 2025-01-01

Plain-language summary

The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing) * Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU) Exclusion Criteria: * Absence of informed consent * Age \< 18 years old

What they're measuring

Evaluation of IgE proteoforms

Timeframe: 4 years

Trial details

NCT IDNCT07328178

SponsorKU Leuven

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-01-01

View on ClinicalTrials.gov More Anaphylaxis trials